17.87 USD
-1.54 (-7.93%)
18.15 USD
+0.28 (+1.57%)
Taking everything into account, NRIX scores 3 out of 10 in our fundamental rating. NRIX was compared to 525 industry peers in the Biotechnology industry. NRIX has a great financial health rating, but its profitability evaluates not so good. NRIX does not seem to be growing, but still is valued expensively.
1. Profitability
1.1 Basic Checks
- NRIX had negative earnings in the past year.
- In the past year NRIX has reported a negative cash flow from operations.
- NRIX had negative earnings in each of the past 5 years.
- In the past 5 years NRIX always reported negative operating cash flow.
1.2 Ratios
- With a Return On Assets value of -46.85%, NRIX perfoms like the industry average, outperforming 53.33% of the companies in the same industry.
- NRIX has a Return On Equity (-65.76%) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -46.85% | ||
| ROE | -65.76% | ||
| ROIC | N/A |
ROA(3y)-37.56%
ROA(5y)-29.63%
ROE(3y)-55.97%
ROE(5y)-43.41%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- NRIX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
- NRIX does not have a ROIC to compare to the WACC, probably because it is not profitable.
- NRIX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
- An Altman-Z score of 4.05 indicates that NRIX is not in any danger for bankruptcy at the moment.
- NRIX has a better Altman-Z score (4.05) than 71.62% of its industry peers.
- There is no outstanding debt for NRIX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 4.05 |
ROIC/WACCN/A
WACC8.88%
2.3 Liquidity
- A Current Ratio of 5.35 indicates that NRIX has no problem at all paying its short term obligations.
- NRIX has a Current ratio of 5.35. This is comparable to the rest of the industry: NRIX outperforms 58.29% of its industry peers.
- A Quick Ratio of 5.35 indicates that NRIX has no problem at all paying its short term obligations.
- NRIX has a Quick ratio (5.35) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 5.35 | ||
| Quick Ratio | 5.35 |
3. Growth
3.1 Past
- NRIX shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -5.19%.
EPS 1Y (TTM)-5.19%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-9.33%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%2.23%
3.2 Future
- NRIX is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 13.18% yearly.
- The Revenue is expected to grow by 40.76% on average over the next years. This is a very strong growth
EPS Next Y-10.37%
EPS Next 2Y-3.82%
EPS Next 3Y-1.02%
EPS Next 5Y13.18%
Revenue Next Year-35.58%
Revenue Next 2Y-12.02%
Revenue Next 3Y13.58%
Revenue Next 5Y40.76%
3.3 Evolution
4. Valuation
4.1 Price/Earnings Ratio
- NRIX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
- Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for NRIX. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-3.82%
EPS Next 3Y-1.02%
5. Dividend
5.1 Amount
- NRIX does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
NURIX THERAPEUTICS INC / NRIX FAQ
What is the ChartMill fundamental rating of NURIX THERAPEUTICS INC (NRIX) stock?
ChartMill assigns a fundamental rating of 4 / 10 to NRIX.
What is the valuation status of NURIX THERAPEUTICS INC (NRIX) stock?
ChartMill assigns a valuation rating of 0 / 10 to NURIX THERAPEUTICS INC (NRIX). This can be considered as Overvalued.
What is the profitability of NRIX stock?
NURIX THERAPEUTICS INC (NRIX) has a profitability rating of 1 / 10.
Can you provide the expected EPS growth for NRIX stock?
The Earnings per Share (EPS) of NURIX THERAPEUTICS INC (NRIX) is expected to decline by -10.37% in the next year.